Business UpdateMay 12, 2026, 07:02 AM
Seres Therapeutics to Present at H.C. Wainwright BioConnect Conference
AI Summary
Seres Therapeutics, Inc. announced that its management will attend and present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference. The presentation is scheduled for May 19, 2026, at 3:30 p.m. ET, with a live webcast accessible via the company's website. Seres Therapeutics is a clinical-stage biotechnology company focused on inflammatory and immune diseases, known for developing VOWST and advancing pipeline candidates like SER-155 and SER-603.
Key Highlights
- Seres Therapeutics management to present at H.C. Wainwright BioConnect.
- Presentation scheduled for May 19, 2026, at 3:30 p.m. ET.
- Live webcast available on the company's investor relations website.
- Company developed VOWST, later divested to Nestlé Health Science.
- SER-155 is Phase 2 ready, pending funding, with Breakthrough Therapy designation.
- SER-603 is in development for inflammatory bowel disease.
Price Impact
More from MCRB